Symbiotec Pharmalab Receives US FDA EIR with VAI Status for Pithampur Facility
Symbiotec Pharmalab Ltd 路 Others (Uncategorized) 路 29 Sept 2026, 4:22 pm
Symbiotec Pharmalab Receives US FDA EIR with VAI Status for Pithampur Facility Symbiotec Pharmalab Limited received an Establishment Inspection Report from the U.S. FDA on 29th Sep'26 for its manufacturing facility located at Pithampur (SEZ), Madhya Pradesh. The regulatory agency classified the inspection outcome as Voluntary Action Indicated (VAI). This follows the regulatory audit conducted at the manufacturing site between 10th Aug'26 and 14th Aug'26, successfully resolving the inspection cycle and supporting ongoing regulatory compliance for U.S. market supplies.
Original exchange filing (PDF)
More announcements from Symbiotec Pharmalab Ltd
- Intimation regarding change in Corporate Identification Number (CIN) and Listing Status of the Company. 路 17 Nov 2026
- Transcript of the Earnings conference call for the Analysts and Investors for the Quarter and Half year ended 路 12 Nov 2026
- Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time .... 路 12 Nov 2026
- Pursuant to Part A of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Audio recording of Conference Call for Analysts and Investors held on November .... 路 06 Nov 2026
- Symbiotec Signs 10 Year take or Pay Agreement to Manufacture Fermentation based alternative protein for EU Innovator 路 06 Nov 2026
- The Monitoring Agency report issued by the CARE Edge Ratings, Monitoring Agency, appointed by the Company for the utilisation and application of funds raised through the IPO of the Company .... 路 06 Nov 2026
- The Investor release being issued by the company, for the quarter and half year ended September 30, 2026 路 06 Nov 2026
- Pursuant to regulations 30 of the SEBI Listing Regulations, Investor Presentation on the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026. 路 06 Nov 2026
